PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization
NCT ID: NCT00358345
Last Updated: 2008-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
347 participants
OBSERVATIONAL
2003-10-31
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study secondary is to enhance NotalVision normative database.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PHP Home Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV)
NCT00359008
Correlation Between Visual Field Defects on Foresee Preferential Hyperacuity Perimeter(PHP) and on Optical Coherence Tomography (OCT) in Patients With Choroidal Neovascularization (CNV)
NCT00692887
Usability of the PreView PHP for Home Use in Intermediate AMD Patients
NCT00776451
Usability of the Foresee Home in Intermediate Age Related Macular Degeneration (AMD) Patients
NCT00748384
Comparison Between Foresee Home and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
NCT01073592
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* A clinical trail with FDA approval device (510K).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Intermediate AMD
No interventions assigned to this group
2
Newly diagnosed CNV
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>50 for AMD subjects
* Age \>18 for Myopic subjects
* VA 20/160 or better in the study eye
* Mental and physical ability to performed a PHP test
Exclusion Criteria
* Previous surgical or laser treatment within the macular erea.
* Concurrent intraocular drug therapy (within 30 days).
* Present of any significant media opacity that preclude a clear veiw of the macula.
* Any non macular related ocular surgery performed within 3 months prior to the study.
* CNV subjects inability to tolerate intravenous fluorscien angiography.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Notal Vision Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
NotalVision
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ofer Sharon, MD
Role: STUDY_DIRECTOR
Notal Vision
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tel Aviv Sourasky medical center
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PHP C9
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.